	Rituximab
Systemic lupus erythematosus
Children
	lupus nephritis
SLE-disease activity index 2 K
rituximab therapy
Bcell depletion
children
age
Clinical disease activity
therapy
patients
RTX
doses
treatment
clinical remission
severe SLE
courses
Lupus activity
years
antiCD 20 monoclonal antibody
CD 20 lymphocytes
clinical response
toxic medications
severe immunosuppression
SLE
long-term toxicity
adults
rituximab
multiple courses
month intervals
hemodialysis
antibody
renal function
proteinuria
systemic lupus
assayed

